Business Standard

Bharat Biotech awaits booster dose nod for intranasal vaccine iNCOVACC

Bharat Biotech did not comment on its plans to make this vaccine available for young children

Bharat Biotech's intranasal Covid vaccine
Premium

The Hyderabad-based company has established large manufacturing capabilities at multiple sites across India — Gujarat, Karnataka, Maharashtra, and Telangana

Sohini Das Mumbai
Bharat Biotech’s intranasal vaccine iNCOVACC has got the Indian regulator’s approval, but there is still some way before one can actually take it.

With almost all the eligible population having taken at least a single shot of a Covid-19 vaccine, the company has no potential market for iNCOVACC as a primary two-dose regimen. The company is waiting for approval for administering the vaccine as a booster shot after Covishield and Covaxin.

Krishna Ella, chairman and managing director of Bharat Biotech, admitted there was hardly any demand. “Despite the lack of demand for Covid-19 vaccines, we continued product development in intra-nasal

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 07 2022 | 7:42 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com